Learn About Gaucher Disease Type 2

View Main Condition: Gaucher Disease

What is the definition of Gaucher Disease Type 2?
Gaucher disease type 2 is an inherited metabolic disorder in which harmful quantities of a fatty substance called glucocerebroside accumulate in the spleen, liver, lungs, bone marrow, and brain. Symptoms usually develop by 3 months of age and include brain damage, seizures, abnormal eye movements, poor ability to suck and swallow, and enlargement of the liver and spleen. Gaucher disease type 2 is caused by genetic changes in the GBA gene. It is inherited in an autosomal recessive pattern.
Save information for later
Sign Up
What are the alternative names for Gaucher Disease Type 2?
  • Gaucher disease type 2
  • GD 2
  • Gaucher disease, acute neuronopathic type
  • Gaucher disease, infantile cerebral
Who are the top Gaucher Disease Type 2 Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What are the latest Gaucher Disease Type 2 Clinical Trials?
A Post Marketing Surveillance (PMS) Study for VPRIV (Velaglucerase Alfa) in India

Summary: The purpose of this post-marketing survey study is to determine the safety and evaluate effectiveness in participants receiving VPRIV when used in the post-marketing setting and to collect and record genetic mutation data from participants with Gaucher disease.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Omics Gaucher Study: Multiomic Approach To Describe The Gaucher Disease Treatment Dynamics In Comparison To Untreated Healthy Volunteers

Summary: The study aims to investigate the transcriptomic and metabolomic changes in blood, plasma and isolated monocytes from Gaucher patients and healthy controls.

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Gaucher Disease Type 2?
Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS).
Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan.
Tired of the same old research?
Check Latest Advances
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.